<DOC>
	<DOC>NCT00043368</DOC>
	<brief_summary>This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.</brief_summary>
	<brief_title>PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<criteria>Immediate (within 4 weeks) prior completion of a clinical trial of PF3512676 Injection alone or in combination with other antineoplastic treatment for malignancy. The patient has received any antineoplastic therapy since completing a prior trial with PF3512676 Injection, or has participated in another clinical trial following participation in a trial with PF3512676 Injection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>CPG 7909 continuation study</keyword>
</DOC>